Naslov
Adiponectin in both Type 1 and Type 2 Diabetes Appears to be Associated with HDL but also with a Level of Inflammation

Autori
Ljubić, Spomenka ; Vučić Lovrenčić, Marijana ; Mileta, Dean ; Metelko, Željko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Diabetes : Abstract book / - : American Diabetes Association, 2007, A335-A335

Skup
American Diabetes Association 67th Scientific Sessions

Mjesto i datum
Chicago (IL), Sjedinjene Američke Države, 22.06.2007. - 23.06.2007

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
adiponectin; HDL cholesterol; diabetes mellitus; inflammatory markers

Sažetak
The aim was to investigate the role of adiponectin (ADN) in diabetes and its connection with obesity, dislipidemia and inflammation. Relevant clinical and laboratory parameters of diabetes, obesity and inflammation have been measured in eighty patients with type 1 diabetes (D1), type 2 diabetes (D2) and a control group (D0). A significant difference (p=0.045) in ADN was found between male (6.35&#177; 3.43) and female patients (9.99&#177; 7.89) (Mann-Whitney U test), as well as between D1 (ADN=12.22&#177; 6.68), D2 (ADN=6.86&#177; 5.42) and D0 (ADN=7.85&#177; 6.47) (ANOVA: F=4.22, df=2, p=0.018). The Turkey post hoc test pointed to a significant difference in ADN between D1 and D2 (p=0.013). ANOVA revealed a significant difference in fasting blood glucose (FBG) [H(2, N=80)=32.2, p<0.0001] and BMI [H(2, N=80)=9.70, p=0.007] between D1, D2 and D0, with higher values in D2 compared to D1 (p<0.01). A difference in CRP existed between D1 (2.17&#177; 2.88), D2 (3.18&#177; 3.00) and D0 (3.72&#177; 3.14) but was not significant. ANOVA revealed a significant difference in ADN within D2 in relation to BMI [<25(A), 25-30(B), >30(C)] (F=6.36, df=2, p=0.003). The Turkey post hoc test indicated a significant difference in ADN between A (ADN=12.44&#177; 11.21) and B (ADN=5.55&#177; 2.20) (p=0.004), and between A and C (ADN=5.84&#177; 1.64) (p=0.007). ANOVA revealed a significant difference in CRP between groups in relation to BMI [H(2, N=46)=13.8, p=0.001] (A-1.72&#177; 1.17, B-2.83&#177; 3.83, C-4.31&#177; 1.96). ADN correlated statistically significantly (p<0.05) with HDL (r=0.78), atherogenic index of plasma (AIP) (r=-0.63), BMI (r=-0.41), diabetes duration (r=0.35) and leukocyte count (r=-0.33). After the stepwise regression procedure for ADN in D1, the best model (R2=0.989) included AIP (p<0.0001), uric acid (UA) (p<0.0001) and homocysteine (p=0.05). Partial R2 for UA was 0.737, indicating that UA was one of the best predictors. Partial R2 for AIP was 0.244. In D2 the best model for ADN (R2=0.725) included HDL (p<0.0001), systolic blood pressure (p=0.059) and fibrinogen (p=0.035). Partial R2 for HDL was 0.636. In D1 the best model for UA (R2=0.399) included CRP (p=0.028), pulse pressure (PP) (p=0.013) and gamma-GT (p=0.066). Partial R2 for CRP was 0.171 and for PP 0.153. Serum ADN appears to be significantly associated with HDL and consequently with AIP, but also with markers of inflammation. Increased ADN level in type 1 compared to type 2 diabetes, aside from insulin resistance in type 2, could also be explained by the anti-inflammatory effect of intensive insulin treatment.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA